Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictive Model for Clinical Cure in Chronic Hepatitis B Inactive HBsAg Carriers Treated With Pegylated Interferon-α
ChiCTR2500113938Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pegylated interferon alpha in Chronic Hepatitis B (CHB) and hepatitis B (HBV) (2 arms), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Quantitative HBV serological markers (HBV five items) at week 72 and Quantitative HBV DNA at week 72. Started Dec 2025; status: recruiting.
02
Drugs
pegylated interferon alpha
03
Conditions
Chronic Hepatitis B (CHB)hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR2500113938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113938.